Table 4.
Analysis of cost-effectiveness of each screening strategy
| Cost-effectiveness Measures | TST | T-SPOT.TB | QFT-GIT | TST/T-SPOT.TB | TST/QFT-GIT |
|---|---|---|---|---|---|
| Total costs of screening | £199,589 | £203,983 | £202,921 | £162,387 | £157,048 |
| Incremental cost of screening (compared to no screening) | £142,442 | £146,836 | £145,774 | £105,240 | £99,901 |
| Active TB cases prevented | 2.98 | 3.70 | 3.47 | 2.83 | 2.65 |
| Cost per active TB case prevented | £67,034 | £55,168 | £58,536 | £57,410 | £59,265 |
| Incremental cost per active case prevented (compared to no screening) | £47,840 | £39,712 | £42,051 | £37,206 | £37,699 |
| Savings per active TB case prevented (compared to TST) | - | £8,128 | £5,790 | £10,634 | £10,141 |
All costs are expressed in British pounds (£). Cost-effectiveness relates to outcomes and costs for entire cohort of 1,000 contacts over the 2 year examination period. (TST - Tuberculin Skin Test, QFT-GIT - Quantiferon-TB Gold-In-Tube)